Team
Team

John Ford, PhD

Advisor

Dr John Ford has 20 years of drug discovery and development experience. As a successful biotechnology entrepreneur he co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (Co-Owner). He is currently the CEO of Enterprise Therapeutics, a company that is developing mutant agnostic mucokinetic drugs approaches for Cystic Fibrosis and other respiratory diseases. At Xention he was responsible for the Kv1.5 ion channel atrial fibrillation project which was partnered to Servier (up to 120M EUR). He was a member of the Executive Team at Dezima (Project Director & COO) that developed TA-8995 for dyslipidaemia (Phase 2b study published in The Lancet) and sold the company to Amgen ($300M upfront, potential deal size of US$1.55bn + royalties). Previous positions include Team Leader for Receptors and Channel Drug Discovery at BioFocus (now owned by Charles River). Dr Ford holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

John Ford